Last reviewed · How we verify
Ketotifen/Indomethacin
Ketotifen is a mast cell stabilizer and H1-receptor antagonist, while indomethacin is a non-selective NSAID that inhibits cyclooxygenase, together reducing allergic inflammation and pain.
Ketotifen is a mast cell stabilizer and H1-receptor antagonist, while indomethacin is a non-selective NSAID that inhibits cyclooxygenase, together reducing allergic inflammation and pain. Used for Allergic conditions (specific indication in phase 3 not publicly detailed).
At a glance
| Generic name | Ketotifen/Indomethacin |
|---|---|
| Also known as | Zaditor, Indocin SR, Tivorbex |
| Sponsor | Sen-Jam Pharmaceutical |
| Drug class | Mast cell stabilizer / NSAID combination |
| Target | H1 receptor, mast cell stabilization, COX-1/COX-2 |
| Modality | Small molecule |
| Therapeutic area | Allergy / Inflammation |
| Phase | Phase 3 |
Mechanism of action
Ketotifen prevents mast cell degranulation and blocks histamine H1 receptors to reduce allergic responses, while indomethacin inhibits COX-1 and COX-2 to decrease prostaglandin and leukotriene production. This combination targets both immediate hypersensitivity and inflammatory pathways, potentially useful in allergic and inflammatory conditions.
Approved indications
- Allergic conditions (specific indication in phase 3 not publicly detailed)
Common side effects
- Gastrointestinal upset
- Drowsiness (ketotifen)
- Headache
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketotifen/Indomethacin CI brief — competitive landscape report
- Ketotifen/Indomethacin updates RSS · CI watch RSS
- Sen-Jam Pharmaceutical portfolio CI